Personalized Medicine And Quality Of Life In Oncology: Contributions From Nuclear Medicine | 46593
Journal of Nuclear Medicine & Radiation Therapy
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Nuclear Physician Specialist, Umhlanga Molecular Imaging and Therapy Centre Personalized medicine has shifted the paradigm
of individualized patient management in evidence-based medicine. In the last 2 decades, advances in targeted radiotherapy
have set the stage for a new group of targeting agents with promising performances. Specific imaging probes are the nuclear fuel for
molecular imaging by Single Photon Emission Tomography (SPECT) or Positron Emission Tomography (PET). The non-invasive
depiction and quantification of biochemical processes with the goal of functional characterization of tumor biology is critical
toward the understanding of tumour behaviour. Interpreting and translating these imaging targets into targeting therapeutic agents
(Theranostics) is fundamental in selecting alternative therapy options, predicting response in therapy and estimating therapeutic
outcome, thus personalizing therapy on a molecular level. There has been increasing weight placed upon quantification of quality of
life in the individual. Generally these agents are well tolerated without serious side effects. This has widened the impact and outcome
of target radiotherapy and generated the theranostics era.